证券代码：300110 证券简称：华仁药业 公告编号：2025-065 华仁药业股份有限公司 关于股东减持计划实施完成的公告 股东红塔创新投资股份有限公司保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。本公司及董事会全体成员保证 公告内容与信息披露义务人提供的信息一致。 华仁药业股份有限公司（以下简称"华仁药业"或"公司"）于2025年8月4日披 露了股东红塔创新投资股份有限公司（以下简称"红塔创新"）《关于持股5%以 上股东减持计划预披露的公告》（公告编号：2025-047），红塔创新计划自减持 计划公告之日起十五个交易日后的三个月内通过集中竞价交易方式减持不超过 公司总股本1%的股份，即不超过11,820,000股。 公司于2025年9月9日披露了《关于持股5%以上股东持股比例变动至5%以下 暨权益变动的提示性公告》（公告编号：2025-060）及《简式权益变动报告书》， 红塔创新持有公司股份比例降至4.999999%，不再是公司持股5%以上股东。 近日，公司收到红塔创新《关于减持华仁药业股份计划实施结果的告知函》， 红塔创新上述减持计划已实施完成。现将具体情况公告如下： ...

Group 1: Stock Performance and Financing - On September 30, Huaren Pharmaceutical's stock increased by 0.62%, with a trading volume of 42.32 million yuan [1] - The financing buy-in amount for Huaren Pharmaceutical on the same day was 4.40 million yuan, while the financing repayment was 5.92 million yuan, resulting in a net financing buy of -1.52 million yuan [1] - As of September 30, the total margin balance for Huaren Pharmaceutical was 249 million yuan, accounting for 6.48% of its market capitalization, indicating a high level compared to the past year [1] Group 2: Business Overview - Huaren Pharmaceutical, established on May 20, 1998, and listed on August 25, 2010, is located in Qingdao, Shandong Province [1] - The company's main business includes large-volume intravenous solutions, peritoneal dialysis solutions, respiratory medications, narcotic medications, raw materials, medical packaging, medical devices, and health products [1] - The revenue composition of Huaren Pharmaceutical is as follows: basic intravenous solutions 40.63%, peritoneal dialysis solutions 34.90%, therapeutic preparations 14.92%, medical devices 8.14%, and others 1.41% [1] Group 3: Shareholder Information and Financial Performance - As of September 20, Huaren Pharmaceutical had 40,500 shareholders, a decrease of 1.46% from the previous period, with an average of 29,156 circulating shares per shareholder, an increase of 1.48% [2] - For the first half of 2025, Huaren Pharmaceutical reported a revenue of 624 million yuan, a year-on-year decrease of 19.13%, and a net profit attributable to shareholders of 37.33 million yuan, down 49.01% year-on-year [2] Group 4: Dividend Information - Since its A-share listing, Huaren Pharmaceutical has distributed a total of 294 million yuan in dividends, with 49.65 million yuan distributed over the past three years [3]

Core Viewpoint - Huaren Pharmaceutical (300110) announced the board's approval to elect Mr. Li Jian as a candidate for the non-independent director of the eighth board of directors [1] Summary by Category - **Company Announcement** - The board of Huaren Pharmaceutical has agreed to elect Mr. Li Jian as a candidate for the non-independent director position [1]

Core Viewpoint - Huarun Pharmaceutical and its subsidiaries have successfully participated in the bidding for the "3+N" alliance procurement project in the Beijing-Tianjin-Hebei region, securing contracts for several products [1] Group 1: Company Participation - Huarun Pharmaceutical and its wholly-owned subsidiaries, Guangxi Yuyuan Pharmaceutical Co., Ltd. and Huarun Pharmaceutical (Rizhao) Co., Ltd., actively engaged in the bidding process for the procurement project [1] - The project is identified as "LH-YD2025-1" and involves both Western medicine and traditional Chinese medicine [1] Group 2: Procurement Results - The Tianjin Pharmaceutical Procurement Center has announced the selection results, confirming that Huarun Pharmaceutical's products, including mixed sugar electrolyte injection, betahistine hydrochloride sodium injection, and hydroxyethyl starch 130/0.4 sodium chloride injection, have been chosen for this procurement [1]

Group 1 - Huarun Pharmaceutical held a temporary board meeting on September 29, 2025, to discuss the election of a non-independent director [1] - For the first half of 2025, Huarun Pharmaceutical's revenue composition was 95.79% from pharmaceutical manufacturing and 4.21% from pharmaceutical commerce [1] - As of the report date, Huarun Pharmaceutical's market capitalization was 3.8 billion yuan [1] Group 2 - The competition between Nongfu Spring and Yibao has intensified, with Nongfu Spring's green bottle launch leading to a significant market share decline for Yibao, dropping nearly 5 percentage points [1]

Core Viewpoint - Huaneng Pharmaceutical (300110.SZ) and its wholly-owned subsidiaries have successfully participated in the bidding for the "3+N" alliance procurement in the Beijing-Tianjin-Hebei region, securing contracts for several products [1] Group 1: Procurement Participation - The company and its subsidiaries actively engaged in the bidding process for the "3+N" alliance procurement, specifically for Western medicine and traditional Chinese medicine [1] - The procurement project number is LH-YD2025-1, indicating a structured approach to the bidding process [1] Group 2: Selected Products and Revenue Impact - The selected products include: - Mixed sugar electrolyte injection with projected sales of 823,200 yuan, accounting for 0.06% of the company's total revenue in 2024 [1] - Betahistine hydrochloride sodium injection with projected sales of 2,220,300 yuan, representing 0.16% of total revenue [1] - Hydroxyethyl starch 130/0.4 sodium chloride injection with projected sales of 9,995,400 yuan, making up 0.74% of total revenue [1] - The total projected sales revenue from these selected products for 2024 is 13,038,900 yuan, which constitutes 0.96% of the company's total revenue [1]

Core Viewpoint - Huarun Pharmaceutical (300110.SZ) and its wholly-owned subsidiaries have successfully participated in the bidding for the "3+N" alliance procurement in the Beijing-Tianjin-Hebei region, securing contracts for several products [1] Group 1: Procurement Participation - The company and its subsidiaries actively engaged in the bidding process for the "3+N" alliance procurement project (Project No: LH-YD2025-1) [1] - The Tianjin Pharmaceutical Procurement Center recently announced the selection results, confirming the company's products as winners in this procurement [1] Group 2: Selected Products and Revenue Impact - The selected products include: - Mixed sugar electrolyte injection with a projected sales revenue of 823,200 yuan for 2024, accounting for 0.06% of the company's total revenue [1] - Betahistine hydrochloride sodium injection with a projected sales revenue of 2,220,300 yuan for 2024, accounting for 0.16% of the company's total revenue [1] - Hydroxyethyl starch 130/0.4 sodium chloride injection with a projected sales revenue of 9,995,400 yuan for 2024, accounting for 0.74% of the company's total revenue [1] - The total projected sales revenue from these selected products for 2024 is 13,038,900 yuan, representing 0.96% of the company's total revenue [1]

Core Insights - Huarun Pharmaceutical and its subsidiaries have successfully participated in the bidding for the "3+N" alliance procurement in the Beijing-Tianjin-Hebei region, securing contracts for several products [1] Group 1: Company Performance - The selected products are expected to generate a total sales revenue of 13.0389 million yuan in 2024, accounting for 0.96% of the company's total revenue for the year [1] - The revenue breakdown for the selected products includes: - Mixed sugar electrolyte injection: 823,200 yuan (0.06% of total revenue) - Betahistine hydrochloride sodium injection: 2,220,300 yuan (0.16% of total revenue) - Hydroxyethyl starch 130/0.4 sodium chloride injection: 9,995,400 yuan (0.74% of total revenue) [1] Group 2: Product Details - The selected products and their specifications include: - Mixed sugar electrolyte injection (500ml) priced at 15.29 yuan per bag, used for hydration and electrolyte maintenance [2] - Betahistine hydrochloride sodium injection (0.02g) priced at 5.76 yuan per bottle, primarily for Meniere's disease and related conditions [2] - Hydroxyethyl starch 130/0.4 sodium chloride injection available in multiple specifications, priced between 3.56 and 6.05 yuan per bag, used for treating and preventing blood volume deficiency [2]

华仁药业股份有限公司董事会 二〇二五年九月二十九日 附件：简历 华仁药业股份有限公司 关于补选第八届董事会非独立董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 证券代码：300110 证券简称：华仁药业 公告编号：2025-062 华仁药业股份有限公司（以下简称"公司"）于 2025 年 9 月 29 日召开第八届董 事会第十一次（临时）会议，审议通过了《关于补选第八届董事会非独立董事的议 案》。经公司控股股东西安曲江天授大健康投资合伙企业（有限合伙）提名，并 经公司董事会提名委员会审核通过，公司董事会同意补选李健先生为公司第八届 董事会非独立董事候选人（李健先生简历详见附件），任期自公司股东会审议通过 之日起至第八届董事会任期届满之日止。该事项尚需提交公司 2025 年第二次临时 股东会审议。本次补选董事完成后，董事会中兼任公司高级管理人员以及由职工代 表担任的董事人数总计不超过公司董事总数的二分之一。 特此公告。 李健先生，1982 年 10 月出生，中国国籍，中共党员，无境外永久居留权， 医学博士，副主任医师。曾先后供职于总后勤部青藏兵站部、 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-064 中选企业 中选产品 适应症 规格 中选价格 采购区域 华仁药业股 份有限公司 混合糖电解 质注射液 不能口服给药或口服给药不能 充分摄取时，补充和维持水分及 电解质，并补给能量。 500ml 15.29 元/袋 北京、天 津、河北 等多个省 （自治 区、直辖 市） 广西裕源药 业有限公司 盐酸倍他司 汀氯化钠注 射液 主要用于美尼尔氏综合征，亦可 用于动脉硬化、缺血性脑血管疾 病及高血压所致体位性眩晕、耳 鸣。 500ml:盐酸倍 他司汀 0.02g 与氯化钠 4.5g 5.76 元/瓶 华仁药业（日 照）有限公司 羟乙基淀粉 130/0.4 氯化 钠注射液 治疗和预防血容量不足，急性等 容血液稀释（ANH）。 250ml-500ml， 共计 5 个规格 3.56-6.05 元 /袋 一、中选产品的基本情况 二、本次中选对公司的影响 本次中选产品 2024 年合计销售收入为 1303.89 万元，占公司 2024 年营业收 入总额的 0.96%。其中混合糖电解质注射液 2024 年销售收入 82.32 万元，占公 司 2024 年营业收入 ...